Synta is set to ROAR

It has been some time since I have opined on Synta Pharmaceuticals (NASDAQ:SNTA). Since my last piece on Seeking Alpha covering this company, which was published on December 30, 2013, I have completed my PhD in epidemiology. As such, it felt it prudent to pick up writing about the biotech and healthcare sectors now that I have returned to Seeking Alpha. I previously made the call that Synta Pharmaceuticals was one of my top picks for 2014, specifically among biotechs working on cancer therapies. To my surprise, there has not been a single focus article on this stock since my last focus article. This is surprising, given that the average analyst price target is still over three times the current share price of the stock. That said, my opinion in December was based on the fact that the company may be sitting on a formulation which if effective, could generate millions, if not billions in revenue and of course result in the stock moving orders of magnitude higher from its then price of around $4.85 per share. Since that time, the stock is down into 2014, losing 17% in value since I made the last call (figure 1). There are several reasons.............READ MORE